Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

BridgeBio Pharma

DB:2CL
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2CL
DB
$3B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

BridgeBio Pharma, Inc. discovers and develops various medicines for genetic diseases. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • BridgeBio Pharma has significant price volatility in the past 3 months.
2CL Share Price and Events
7 Day Returns
1.7%
DB:2CL
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-
DB:2CL
-7.4%
DE Biotechs
-14.2%
DE Market
2CL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BridgeBio Pharma (2CL) 1.7% -2.5% -22% - - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • No trading data on 2CL.
  • No trading data on 2CL.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

2CL Value

 Is BridgeBio Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BridgeBio Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BridgeBio Pharma.

DB:2CL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:2CL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (2.75%))
1.048
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.05
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.048 * 5.44%)
5.31%

Discounted Cash Flow Calculation for DB:2CL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BridgeBio Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:2CL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.31%)
2020 -277.00 Analyst x3 -263.04
2021 -220.67 Analyst x3 -198.98
2022 -226.33 Analyst x3 -193.80
2023 -76.50 Analyst x2 -62.20
2024 101.00 Analyst x2 77.98
2025 151.37 Est @ 49.87% 110.98
2026 204.03 Est @ 34.79% 142.05
2027 253.48 Est @ 24.24% 167.59
2028 296.19 Est @ 16.85% 185.95
2029 330.78 Est @ 11.68% 197.20
Present value of next 10 years cash flows $163.00
DB:2CL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $330.78 × (1 + -0.39%) ÷ (5.31% – -0.39%)
$5,782.07
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,782.07 ÷ (1 + 5.31%)10
$3,447.08
DB:2CL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $163.00 + $3,447.08
$3,610.08
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,610.08 / 123.77
$29.17
DB:2CL Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:2CL represents 0.86892x of NasdaqGS:BBIO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86892x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 29.17 x 0.86892
€25.35
Value per share (EUR) From above. €25.35
Current discount Discount to share price of €23.40
= -1 x (€23.40 - €25.35) / €25.35
7.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BridgeBio Pharma is available for.
Intrinsic value
8%
Share price is €23.4 vs Future cash flow value of €25.35
Current Discount Checks
For BridgeBio Pharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BridgeBio Pharma's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • BridgeBio Pharma's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BridgeBio Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BridgeBio Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2CL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.48
NasdaqGS:BBIO Share Price ** NasdaqGS (2020-04-08) in USD $26.93
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BridgeBio Pharma.

DB:2CL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:BBIO Share Price ÷ EPS (both in USD)

= 26.93 ÷ -2.48

-10.86x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BridgeBio Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • BridgeBio Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does BridgeBio Pharma's expected growth come at a high price?
Raw Data
DB:2CL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.86x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
26.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BridgeBio Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BridgeBio Pharma's assets?
Raw Data
DB:2CL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $3.30
NasdaqGS:BBIO Share Price * NasdaqGS (2020-04-08) in USD $26.93
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:2CL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:BBIO Share Price ÷ Book Value per Share (both in USD)

= 26.93 ÷ 3.30

8.15x

* Primary Listing of BridgeBio Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BridgeBio Pharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess BridgeBio Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BridgeBio Pharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2CL Future Performance

 How is BridgeBio Pharma expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
26.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BridgeBio Pharma expected to grow at an attractive rate?
  • BridgeBio Pharma's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • BridgeBio Pharma's earnings growth is expected to exceed the Germany market average.
  • BridgeBio Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2CL Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2CL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 26.6%
DB:2CL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 55.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2CL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2CL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 974 1,058 196 4
2023-12-31 446 301 -174 4
2022-12-31 118 -254 -352 6
2021-12-31 101 -273 -285 7
2020-12-31 15 -338 -336 7
2020-04-09
DB:2CL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 41 -254 -261
2019-09-30 27 -224 -239
2019-06-30 -212 -203
2019-03-31 -178 -168
2018-12-31 -137 -131
2017-12-31 -40 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BridgeBio Pharma's earnings are expected to grow significantly at over 20% yearly.
  • BridgeBio Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2CL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from BridgeBio Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2CL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.05 6.99 -2.15 4.00
2023-12-31 -1.46 1.37 -3.30 4.00
2022-12-31 -2.75 -2.04 -3.45 5.00
2021-12-31 -2.42 -1.29 -3.24 6.00
2020-12-31 -2.88 -2.35 -3.64 6.00
2020-04-09
DB:2CL Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.48
2019-09-30 -4.73
2019-06-30 -10.90
2019-03-31 -9.16
2018-12-31 -2.12
2017-12-31 -1.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BridgeBio Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess BridgeBio Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BridgeBio Pharma has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2CL Past Performance

  How has BridgeBio Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BridgeBio Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BridgeBio Pharma does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare BridgeBio Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BridgeBio Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BridgeBio Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BridgeBio Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2CL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 40.56 -260.59 94.35 209.95
2019-09-30 26.74 -239.06 73.76 203.66
2019-06-30 -203.43 60.51 179.53
2019-03-31 -167.94 54.48 151.10
2018-12-31 -130.75 43.59 140.07
2017-12-31 -30.57 13.30 30.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BridgeBio Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BridgeBio Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BridgeBio Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BridgeBio Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BridgeBio Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2CL Health

 How is BridgeBio Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BridgeBio Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BridgeBio Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BridgeBio Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BridgeBio Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BridgeBio Pharma Company Filings, last reported 3 months ago.

DB:2CL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 475.98 91.79 545.99
2019-09-30 524.27 75.02 536.05
2019-06-30 201.54 75.00 293.80
2019-03-31 302.83 54.86 373.03
2018-12-31 377.36 54.51 436.09
2017-12-31 85.77 0.00 92.00
  • BridgeBio Pharma's level of debt (19.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if BridgeBio Pharma's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BridgeBio Pharma has sufficient cash runway for 2.1 years based on current free cash flow.
  • BridgeBio Pharma has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 60.5% each year.
X
Financial health checks
We assess BridgeBio Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BridgeBio Pharma has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2CL Dividends

 What is BridgeBio Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BridgeBio Pharma dividends. Estimated to be 0% next year.
If you bought €2,000 of BridgeBio Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BridgeBio Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BridgeBio Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2CL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2CL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BridgeBio Pharma has not reported any payouts.
  • Unable to verify if BridgeBio Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BridgeBio Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BridgeBio Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of BridgeBio Pharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess BridgeBio Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BridgeBio Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BridgeBio Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2CL Management

 What is the CEO of BridgeBio Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Neil Kumar
COMPENSATION $450,000
AGE 40
TENURE AS CEO 5 years
CEO Bio

Dr. Neil Kumar, Ph.D., is a co-founder and has served as BridgeBio Pharma, Inc.'s Chief Executive Officer and a member of board of directors since April 2015. He serves as the Chief Executive Officer and Director at Eidos Therapeutics Inc. Dr. Kumar served as a Principal at Third Rock Ventures, LLC. He joined Third Rock Ventures in 2011 and supported and managed various portfolio companies and focused on new company formation and due diligence. Dr. Kumar served as an Interim Head of Business Development and Operations at MyoKardia, Inc. He served as an Associate Principal at McKinsey & Company, where he developed strategies for pharmaceutical and medical device companies and helped lead McKinsey's Personalized Medicine efforts. He was involved in the formation of a gene chip startup. Dr. Kumar was a Technical Consultant for AstraZeneca’s pathway signaling group. He is the author of several peer-reviewed papers in the fields of oncology and systems biology. He holds B.S. and M.S. degrees in Chemical Engineering from Stanford University and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.

CEO Compensation
  • Insufficient data for Neil to compare compensation growth.
  • Neil's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BridgeBio Pharma management team in years:

1.4
Average Tenure
45
Average Age
  • The average tenure for the BridgeBio Pharma management team is less than 2 years, this suggests a new team.
Management Team

Neil Kumar

TITLE
Co-Founder
COMPENSATION
$450K
AGE
40
TENURE
5 yrs

Brian Stephenson

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
38
TENURE
1.5 yrs

Uma Sinha

TITLE
Chief Scientific Officer
COMPENSATION
$3M
AGE
62
TENURE
4 yrs

Charles Homcy

TITLE
Chairman of Pharmaceuticals & Director
COMPENSATION
$200K
AGE
71
TENURE
1.2 yrs

Richard Scheller

TITLE
Chairman of Research & Development and Director
COMPENSATION
$100K
AGE
66
TENURE
1.3 yrs

Brian Stolz

TITLE
Chief Operating Officer
AGE
45
TENURE
0.5 yrs

Yi Yau

TITLE
Chief Accounting Officer
TENURE
0.5 yrs

Cameron Turtle

TITLE
Senior Vice President of Portfolio Management & Corporate Development
AGE
29
TENURE
2.3 yrs

Frank McCormick

TITLE
Chairman of Oncology
AGE
69
TENURE
1 yrs

Michael Henderson

TITLE
Senior Vice President of Asset Acquisition
AGE
29
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the BridgeBio Pharma board of directors in years:

1.8
Average Tenure
55
Average Age
  • The average tenure for the BridgeBio Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Neil Kumar

TITLE
Co-Founder
COMPENSATION
$450K
AGE
40
TENURE
5 yrs

Charles Homcy

TITLE
Chairman of Pharmaceuticals & Director
COMPENSATION
$200K
AGE
71
TENURE
1.4 yrs

Richard Scheller

TITLE
Chairman of Research & Development and Director
COMPENSATION
$100K
AGE
66
TENURE
2.3 yrs

Eric Aguiar

TITLE
Independent Director
AGE
57
TENURE
1.1 yrs

Ali Satvat

TITLE
Independent Director
AGE
42
TENURE
4.1 yrs

Jim Momtazee

TITLE
Independent Director
AGE
47
TENURE
4.1 yrs

Jennifer Cook

TITLE
Director
AGE
53
TENURE
0.3 yrs

Ron Daniels

TITLE
Director
AGE
59
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
03. Jul 19 Buy KKR & Co. Inc. Company 01. Jul 19 01. Jul 19 2,647,100 €15.02 €39,771,619
03. Jul 19 Buy Uma Sinha Individual 01. Jul 19 01. Jul 19 14,000 €15.02 €210,344
03. Jul 19 Buy Michael Henderson Individual 01. Jul 19 01. Jul 19 7,000 €15.02 €105,172
03. Jul 19 Buy Brian Stephenson Individual 01. Jul 19 01. Jul 19 55,500 €15.02 €833,865
28. Jun 19 Buy Viking Global Investors LP Company 27. Jun 19 27. Jun 19 4,705,900 €14.96 €70,384,264
X
Management checks
We assess BridgeBio Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BridgeBio Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2CL News

Simply Wall St News

2CL Company Info

Description

BridgeBio Pharma, Inc. discovers and develops various medicines for genetic diseases. The company has a pipeline of approximately 20 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; BBP-831/infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor to treat FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company is also developing BBP-418 for the treatment of limb-girdle muscular dystrophy type 2i; BBP-870/ fosdenopterin to treat molybdenum cofactor deficiency; BBP-671 to treat pantothenate kinase associated neurodegeneration; BBP-711 for the treatment of primary hyperoxaluria and frequent stone formers; BBP-761 to treat leber’s hereditary optic neuropathy; and BBP-305 / encaleret to treat autosomal dominant hypocalcemia type 1 and hypoparathyroidism. In addition, it is involved in the development of; BBP-551 to treat inherited retinal disease; BBP-472 to treat autism-spectrum disorder; BBP-009/Patidegib to treat gorlin syndrome and high-frequency basal cell carcinoma; BBP-589/PTR-01 to treat recessive dystrophic epidermolysis bullosa; BBP-681 to treat venous and lymphatic malformations; BBP-561 to treat netherton syndrome; BBP-398 to treat cancer; BBP-954 to treat solid and hematological cancers; BBP-812 for canavan disease; and BBP-815 to treat nonsyndromic hearing loss. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Details
Name: BridgeBio Pharma, Inc.
2CL
Exchange: DB
Founded: 2015
$3,065,030,453
123,765,465
Website: http://bridgebio.com
Address: BridgeBio Pharma, Inc.
421 Kipling Street,
Palo Alto,
California, 94301,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS BBIO Common Stock Nasdaq Global Select US USD 27. Jun 2019
DB 2CL Common Stock Deutsche Boerse AG DE EUR 27. Jun 2019
Number of employees
Current staff
Staff numbers
248
BridgeBio Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 00:15
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/02
Last earnings filing: 2020/03/03
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.